News – Page 1010 – Endpoints News

J&J has decided — pharma giant dumps its development deal on Geron’s imetelstat, shattering shares

7 years ago

Nasdaq triple IPO play brings in $345M as the big biotech party rocks on

7 years ago

Eli Lilly picks up an oral GLP-1 diabetes drug from a big Roche sub for $50M in cash-plus deal — and it’s not a ...

7 years ago

Fattaey out, Dentzer up at Curis; Belgian investors back Spanish orphan drug biotech; Verastem scores China deal

7 years ago

AMAG expands maternal health pipeline, bags late-stage orphan drug for $12.5M

7 years ago

AstraZeneca-backed Entasis Therapeutics joins the IPO class of 2018 with a weak debut price

7 years ago

Aldeyra shares soar on positive PhII dry eye data — but lose some steam on second look

7 years ago

A player in the bustling microbiome R&D arena promotes its CSO to the top post -- just ahead of a PhII NASH study

7 years ago

Merck board waves off a forced retirement for CEO Ken Frazier, happy to extend his reign

7 years ago

Lyra pockets $29.5M to push ear, nose, throat applications of implant tech from Langer, Whitesides

7 years ago

Alexion gambles on an early-stage drug for rare diseases, bagging Apple Tree-backed Syntimmune in $1.2B buyout

7 years ago

Guest column: The 3 big waves reshaping investment strategies in early-stage biotech

7 years ago

GSK's vaccine arm lays claim to a major breakthrough on tuberculosis

7 years ago

Takeda highlights promising frontline results for ALK+ NSCLC drug Alunbrig; TGTX shares plunge on PhIII snafu

7 years ago

Gilead's storied hep C franchise will now include a generic drug operation

7 years ago

Roche's IMpower133 offers a glimpse at rare progress in fight against small cell lung cancer

7 years ago

Researchers point to R&D treaty to spur new infectious disease treatments

7 years ago

AstraZeneca spells out a major drop in the risk of death for stage 3 NSCLC patients taking Imfinzi — and why that's ...

7 years ago

Praveen Tipirneni's team at Morphic reels in an $80M round as they turn into the last stretch to the clinic — and a ...

7 years ago

Cash-strapped Gemphire lets go of five staffers as it contends with a clinical hold

7 years ago

Chopping close to home, Novartis outlines plans to ax or move about 2,600 more jobs in another wave of global ...

7 years ago

An autoimmune upstart turns PD-L1 around to blaze a new approach to diabetes, multiple sclerosis

7 years ago

Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success

7 years ago

AstraZeneca CEO Pascal Soriot: 'I'm the lowest-paid CEO in the whole industry'

7 years ago

First page Previous page 1007 1008 100910101011 1012 1013 Next page Last page